Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.81 |
| ▸ | PTGFR | P43088 | 7/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.58 |
| ▸ | SLCO2A1 | Q92959 | 2/20 | 0.58 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.58 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.58 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.58 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.50 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.50 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38663703 | 1.00 | MEN1 (0.81) | MEN1KMT2APTGFRALDH1A1LMNA | |
| SCHEMBL29559217 | 1.00 | MEN1 (0.81) | MEN1KMT2APTGFRALDH1A1LMNA | |
| SCHEMBL13179231 | 1.00 | MEN1 (0.81) | MEN1KMT2APTGFRALDH1A1LMNA | |
| Thromboxane B2 SCHEMBL15263306 | 0.90 | MEN1 (1.00) | MEN1KMT2APTGFRALDH1A1LMNA | |
| Thromboxane B2 SCHEMBL13179230 | 0.90 | MEN1 (1.00) | MEN1KMT2APTGFRALDH1A1LMNA | |
| Thromboxane B2 SCHEMBL38223 | 0.90 | MEN1 (1.00) | MEN1KMT2APTGFRALDH1A1LMNA | |
| Thromboxane B2 SCHEMBL21820779 | 0.90 | MEN1 (1.00) | MEN1KMT2APTGFRALDH1A1LMNA | |
| Thromboxane B2 SCHEMBL22972728 | 0.90 | MEN1 (1.00) | MEN1KMT2APTGFRALDH1A1LMNA | |
| Thromboxane B2 SCHEMBL23646053 | 0.87 | MEN1 (0.77) | MEN1KMT2APTGFRALDH1A1LMNA | |
| SCHEMBL31254102 | 0.87 | MEN1 (0.84) | MEN1KMT2APTGFRALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026106210-A1 | METABOLITE BIOMARKER FOR PREDICTING THERAPEUTIC RESPONSE OF BIOLOGICAL AGENTS IN ASTHMA | 재단법인 아산사회복지재단 | 2026-05-21 | — | — | WO | disclosed |
| WO-2024242465-A1 | LIPID METABOLITE BIOMARKER FOR PREDICTING ASTHMA TREATMENT RESPONSE TO BIOLOGICAL AGENT AND USE THEREOF | 재단법인 아산사회복지재단 | 2024-11-28 | — | — | WO | disclosed |
| CN-115656400-B | Be used for detecting 11-dehydrothromboxane B in urine 2 Liquid chromatography-tandem mass spectrometry method and kit | 大连博源医学科技有限公司 | 2023-08-18 | — | — | CN | disclosed |
| US-20230129262-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS OF THROMBOXANE A2 RECEPTOR ANTAGONIST FOR THE TREATMENT OF COVID-19 | OGLETREE MARTIN (US) | 2023-04-27 | — | — | US | disclosed |
| EP-4125882-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS OF THROMBOXANE A2 RECEPTOR ANTAGONIST FOR THE TREATMENT OF COVID-19 | Ogletree, Martin (US) | 2023-02-08 | — | — | EP | disclosed |
| CN-115656400-A | Method for detecting 11-dehydrothromboxane B in urine 2 Liquid chromatography-tandem mass spectrometry method and kit | 大连博源医学科技有限公司 | 2023-01-31 | — | — | CN | disclosed |
| EP-4119131-A1 | DRY POWDER FORMULATIONS FOR INHALATION | Otitopic Inc. (US) | 2023-01-18 | — | — | EP | disclosed |
| EP-3107548-B1 | DRY POWDER FORMULATIONS FOR INHALATION | OTITOPIC INC (US) | 2022-06-08 | — | — | EP | disclosed |
| CN-114404425-A | Inhibitor of phosphodiesterase and application thereof | 南京中医药大学 | 2022-04-29 | — | — | CN | disclosed |
| EP-3638807-B1 | MIRNA-574-5P AS A BIOMARKER FOR STRATIFICATION OF PROSTAGLANDIN E-DEPENDENT TUMORS | FRAUNHOFER GES FORSCHUNG (DE) | 2022-03-30 | — | — | EP | disclosed |
| EP-0578780-B1 | SUPPRESSION OF THROMBOXANE LEVELS BY PERCUTANEOUS ADMINISTRATION OF ASPIRIN | KEIMOWITZ RUDOLPH M D (US) | 2003-07-02 | — | — | EP | disclosed |
| EP-0627918-B1 | NEW USE OF OMEGA-3-FATTY ACIDS | FRESENIUS KABI AB (SE) | 2001-10-31 | — | — | EP | disclosed |
| EP-0377439-B1 | Controlled-release, low-dose aspirin | STERLING WINTHROP INC (US) | 1995-09-13 | — | — | EP | disclosed |
| EP-0336647-B1 | Determination of arachidonic acid derivatives and kits therefore | SANKYO CO (JP) | 1994-07-13 | — | — | EP | disclosed |
| EP-0578780-A1 | SUPPRESSION OF THROMBOXANE LEVELS BY PERCUTANEOUS ADMINISTRATION OF ASPIRIN | GUNDERSON MEDICAL FOUNDATION, LTD. (US) | 1994-01-19 | — | — | EP | disclosed |
| WO-1992020343-A1 | SUPPRESSION OF THROMBOXANE LEVELS BY PERCUTANEOUS ADMINISTRATION OF ASPIRIN | GUNDERSON MEDICAL FOUNDATION, LTD. (US) | 1992-11-26 | — | — | WO | disclosed |
| EP-0166583-B1 | COMPOSITIONS FOR ENZYME IMMUNOASSAY OF PROSTAGLANDINS | ONO PHARMACEUTICAL CO., LTD. (JP) | 1991-09-18 | — | — | EP | disclosed |
| EP-0377439-A2 | Controlled-release, low-dose aspirin | STERLING WINTHROP INC. (US) | 1990-07-11 | — | — | EP | disclosed |
| EP-0336647-A2 | Determination of arachidonic acid derivatives and kits therefore | Sankyo Company Limited (JP) | 1989-10-11 | — | — | EP | disclosed |
| EP-0166583-A2 | Compositions for enzyme immunoassay of prostaglandins | ONO PHARMACEUTICAL CO., LTD. (JP) | 1986-01-02 | — | — | EP | disclosed |